



May 18, 2026

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (E), Mumbai - 400 051, Maharashtra.

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001, Maharashtra.

Symbol: STAR

Scrip Code: 532531

Dear Madam/ Sir,

Sub: Press Release

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

Please find enclosed herewith Press Release issued by the Company titled:

**“Strides Delivers Strong Performance with FY26 EBITDA at ₹9,253m,
Operational PAT at ₹5,181m, 50% YoY Growth”**

The Board Meeting for considering audited financial results of the Company for the quarter and financial year ended March 31, 2026 commenced at 12:30 hrs IST and concluded at 14:15 hrs IST.

The above information will also be available on website of the Company at www.strides.com.

This is for your information and records.

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary & Compliance Officer
ICSI Membership No.: A30515

Encl. as above

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru – 560 076, India | **Tel:** +91 80 6784 0000

Regd. Off: 'Cyber One', Unit No. 902, Plot No. 4&6, Sector 30A, Vashi, Navi Mumbai – 400 703, India | **Tel:** +91 22 2789 2924/3199

corpcomm@strides.com; www.strides.com

Strides Delivers Strong Performance with FY26 EBITDA at ₹9,253m, Operational PAT at ₹5,181m, 50% YoY Growth

Ex-US Markets Outperform with 21% YoY Revenue Growth; Disciplined Execution Expands EBITDA Margin to 19%

Strides Board Recommends a Dividend of ₹5 per share

FY2026 Performance Highlights

- US Market Revenue at ₹24,897m (\$284m), Grew 2% YoY
- Ex-US Market Revenue at ₹22,404m (\$254m), reported a strong growth of 21% YoY
- Reported Net Debt at ₹14,365m, impacted by Fx (₹) depreciation of ₹1,115m
- Net Debt to EBITDA improved to 1.55x in FY26 from 1.9x in FY25
- RoCE increased to 15.8% in FY26 from 14.9% in FY25
- Operational PAT at ₹5,181m, Grew 50.3% YoY
- Operational EPS at ₹56.2

Bangalore, India, 18th May 2026 - Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q4FY26) and Full Year (FY26) ended March 31, 2026.

Financial Highlights (In ₹m)

Particulars	Q4FY26	Q4FY25	YoY	Q3FY26	QoQ	FY26	FY25	YoY
Revenue	13,235	11,904	11.2%	11,946	10.8%	48,587	45,653	6.4%
Gross Margin	7,872	6,914	13.9%	7,317	7.6%	29,000	25,854	12.2%
Gross Margin %	59.5%	58.1%	140bps	61.2%	-170bps	59.7%	56.6%	310bps
EBITDA	2,397	2,179	10.0%	2,359	1.6%	9,253	8,208	15.3%
EBITDA %	18.1%	18.3%	-20bps	19.8%	-170bps	19.0%	17.6%	140bps
Operational PAT	1,357	1,130	20.0%	1,282	5.9%	5,181	3,447	50.3%
Operational EPS (₹)	14.7	12.3	20.0%	13.9	5.8%	56.2	37.5	50.1%
Reported PAT	1,293	856	51.0%	2,081	-37.9%	5,745	4,094	40.3%
Reported EPS (₹)	13.8	8.9	54.3%	21.9	-37.2%	60.3	44.0	37.0%

Reported PAT = PAT from continuing operations; Operational PAT = Reported PAT excluding exceptional items and one time income

Badree Komandur, MD & Group CEO, commented on the performance and said, “Strides continued to deliver strong performance across profitability, efficiency, and growth metrics during FY26. This was primarily driven by the Ex-US markets, which recorded a growth of 21% YoY. Our continued focus on profitability drove gross margin expansion of 310bps YoY and EBITDA margin improvement of 140bps YoY to 19%. Operational PAT and EPS grew by 50% YoY, reflecting strong operating leverage. Our calibrated strategy in Ex-US markets is delivering results, with these markets outpacing overall company growth. The US business remained stable during the year, though impacted by a weaker flu season in the second half. Despite ongoing geopolitical uncertainties and a challenging external environment, we are committed to delivering to long term sustainable and profitable growth.”

About Strides

Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donor-funded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.

For further information, please contact:

Investor Relations Vikesh Kumar: Group CFO investor-relations@strides.com Saurabh Ambaselkar: +91 99609 31220 saurabh.ambaselkar@strides.com Strides Pharma Science Limited Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076	Corporate Communication Pallavi Panchmatia: +91 80 6784 0193 Pallavi.panchmatia@strides.com Abhilash Mukherjee: +91 89044 28907 Abhilash.Mukherjee@strides.com Adrita Chatterjee: +91 92842 40813 adrita.chatterjee@adfactorspr.com
---	---